Efficacy and Safety Outcomes Among Treatment-Experienced Women and Men Treated with Etravirine in Gender, Race and Clinical Experience

Efficacy and Safety Outcomes Among Treatment-Experienced Women and Men Treated with Etravirine in Gender, Race and Clinical Experience

The GRACE (Gender, Race and Clinical Experience) trial enrolled treatment-experienced, HIV-1-infected patients, mainly women, in North America, to assess outcomes with a darunavir/ritonavir-based regimen, which could include etravirine (ETR). We present outcomes at week 48 for men and women receivin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS research and human retroviruses 2012-06, Vol.28 (6), p.544-551
Hauptverfasser: HODDER, Sally, JAYAWEERA, Dushyantha, MRUS, Joseph, RYAN, Robert, WITEK, James
Format: Artikel
Sprache:eng
Schlagworte:
Acquired immune deficiency syndrome
Acquired Immunodeficiency Syndrome - drug therapy
Acquired Immunodeficiency Syndrome - epidemiology
Acquired Immunodeficiency Syndrome - immunology
Adult
AIDS/HIV
Anti-HIV Agents - therapeutic use
Biological and medical sciences
Clinical trials
Darunavir
Diarrhea
Drug Resistance, Multiple, Viral - immunology
Ethnic groups
Female
Females
Fundamental and applied biological sciences. Psychology
Gender
HIV Protease Inhibitors - therapeutic use
HIV-1 - immunology
Human immunodeficiency virus 1
Human viral diseases
Humans
Hypertriglyceridemia
Infectious diseases
Male
Males
Medical sciences
Microbiology
Miscellaneous
Nausea
North America - epidemiology
Pyridazines - therapeutic use
Races
Retrovirus
Ritonavir - therapeutic use
RNA
RNA, Viral - drug effects
Sex Distribution
Sex Factors
Side effects
Statistical analysis
Sulfonamides - therapeutic use
Treatment Outcome
Viral diseases
Viral Load - drug effects
Virology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The GRACE (Gender, Race and Clinical Experience) trial enrolled treatment-experienced, HIV-1-infected patients, mainly women, in North America, to assess outcomes with a darunavir/ritonavir-based regimen, which could include etravirine (ETR). We present outcomes at week 48 for men and women receiving ETR. Virologic response (HIV-1 RNA
ISSN:0889-2229
1931-8405
DOI:10.1089/aid.2011.0118